Switching and discontinuation of participant-masked randomization to a copper or levonorgestrel intrauterine device when presenting for emergency contraception
Contraception · 2023-02 · 118 · 109893
DOI: 10.1016/j.contraception.2022.09.131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contraception, 2023-02. Verfasst von Jessica Kaplan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Southwest Medical Group Women's & Family Health, Cortez, CO, United States. Hauptthemen laut MEDLINE: Contraception, Postcoital, Intrauterine Devices, Medicated, Intrauterine Devices, Copper. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCRR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: Examine intrauterine device (IUD) switching or discontinuation up to 6 months after participant-masked randomization to different IUDs. STUDY DESIGN: Participants were randomized 1:1 to the copper T380A or levonorgestrel 52 mg IUD for emergency contraception and informed they could switch IUD type without cost at any time. RESULTS: Of the 327 subjects allocated to the levonorgestrel IUD, 7 (2.1%) switched their IUD type by 6 months versus 18 (5.5%) of the 328 copper IUD users (RR: 0.4 [95% CI: 0.2, 0.9], p = 0.03). Six-month IUD discontinuation occurred in 34 (10.4%) levonorgestrel and 35 (10.7%) copper IUD users. CONCLUSION: Individuals randomly assigned to IUD type at presentation for emergency contraception continue their assigned IUDs at high rates over 6 months. IMPLICATIONS: While many recruited individuals declined enrollment, those who accepted randomization had high continuation rates; the high continuation and low cross-over supports using IUD randomization as a tool for future investigation. Participants' similar rates of and reasons for switching and discontinuation by IUD type over the study period may impact clinical counseling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Southwest Medical Group Women's & Family Health, Cortez, CO, United States.
- Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, United States.
- Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA, United States. Electronic address: kefay@bwh.harvard.edu.
Förderung
- NICHD NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health
- National Center for Research Resources
- Merck
- National Center for Advancing Translational Sciences
Zitieren
APA
Kaplan, J., Turok, D. K., Gero, A., Kaiser, J. E., Simmons, R. G., & Fay, K. E. (2023). Switching and discontinuation of participant-masked randomization to a copper or levonorgestrel intrauterine device when presenting for emergency contraception. Contraception, 118, 109893. https://doi.org/10.1016/j.contraception.2022.09.131
Vancouver
Kaplan J, Turok DK, Gero A, Kaiser JE, Simmons RG, Fay KE. Switching and discontinuation of participant-masked randomization to a copper or levonorgestrel intrauterine device when presenting for emergency contraception. Contraception. 2023;118:109893. doi:10.1016/j.contraception.2022.09.131
BibTeX
@article{Kaplan2023,
author = {Kaplan, Jessica and Turok, David K and Gero, Alexandra and Kaiser, Jennifer E and Simmons, Rebecca G and Fay, Kathryn E},
title = {Switching and discontinuation of participant-masked randomization to a copper or levonorgestrel intrauterine device when presenting for emergency contraception},
journal = {Contraception},
year = {2023},
volume = {118},
pages = {109893},
doi = {10.1016/j.contraception.2022.09.131}
}
EUVIMED